FAS and cancer: Meanwhile, growing evidence has suggested that the downregulation of FAS, by short hairpin RNA (shRNA) or small interfering RNA (siRNA), can suppress cancer phenotype and, importantly, reverse drug resistance in cancers, providing direct evidence supporting FAS as a feasible target for cancers.